RELATIVITY-047: Phase II/III Trial of First-line Relatlimab + Nivolumab vs Nivolumab Alone in Advanced Melanoma

June 4-8, 2021; Online at https://conferences.asco.org/am
Dual LAG-3 and PD-1 inhibition with a fixed-dose combination of relatlimab + nivolumab demonstrated superior PFS compared with nivolumab alone in patients with advanced melanoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 338 KB
Released: June 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Related Content

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the impact of new data on treatment algorithms in melanoma.

Jeffrey S. Weber, MD, PhD
Program Director
person default Allison Betof Warner, MD, PhD Hussein Tawbi, MD
Released: September 10, 2021

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the changing therapeutic landscape in advanced melanoma.

person default Allison Betof Warner, MD, PhD Hussein Tawbi, MD Jeffrey S. Weber, MD, PhD Released: September 7, 2021

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

This commentary by Jeffrey Weber, MD, PhD, offers expert insight on recent clinical data with neoadjuvant therapy in melanoma from Clinical Care Options (CCO)

Jeffrey S. Weber, MD, PhD Released: July 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue